TY - JOUR AU - Steinberg, J. AU - Webber, C. PY - 2013 DA - 2013// TI - The roles of FMRP-regulated genes in autism spectrum disorder: single- and multiple-hit genetic etiologies JO - Am J Hum Genet VL - 93 UR - https://doi.org/10.1016/j.ajhg.2013.09.013 DO - 10.1016/j.ajhg.2013.09.013 ID - Steinberg2013 ER - TY - JOUR AU - Lozano, R. AU - Martinez-Cerdeno, V. AU - Hagerman, R. J. PY - 2015 DA - 2015// TI - Advances in the understanding of the gabaergic neurobiology of FMR1 expanded alleles leading to targeted treatments for Fragile X Spectrum disorder JO - Curr Pharm Des VL - 21 UR - https://doi.org/10.2174/1381612821666150914121038 DO - 10.2174/1381612821666150914121038 ID - Lozano2015 ER - TY - JOUR AU - Cordeiro, L. AU - Ballinger, E. AU - Hagerman, R. AU - Hessl, D. PY - 2011 DA - 2011// TI - Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization JO - J Neurodev Disord VL - 3 UR - https://doi.org/10.1007/s11689-010-9067-y DO - 10.1007/s11689-010-9067-y ID - Cordeiro2011 ER - TY - JOUR AU - Weber, J. AU - Smith, E. AU - Berry-Kravis, E. AU - Cadavid, D. AU - Hessl, D. AU - Erickson, C. PY - 2019 DA - 2019// TI - Voice of people with fragile X syndrome and their families: reports from a survey on treatment priorities JO - Brain Sci VL - 9 UR - https://doi.org/10.3390/brainsci9020018 DO - 10.3390/brainsci9020018 ID - Weber2019 ER - TY - JOUR AU - Crawford, D. C. AU - Acuña, J. M. AU - Sherman, S. L. PY - 2001 DA - 2001// TI - FMR1 and the fragile X syndrome: human genome epidemiology review JO - Genet Med VL - 3 UR - https://doi.org/10.1097/00125817-200109000-00006 DO - 10.1097/00125817-200109000-00006 ID - Crawford2001 ER - TY - JOUR AU - Jung, K. -. M. AU - Sepers, M. AU - Henstridge, C. M. AU - Lassalle, O. AU - Neuhofer, D. AU - Martin, H. PY - 2012 DA - 2012// TI - Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome JO - Nat Commun VL - 3 ID - Jung2012 ER - TY - JOUR AU - Mouslech, Z. AU - Valla, V. PY - 2009 DA - 2009// TI - Endocannabinoid system: an overview of its potential in current medical practice JO - Neuro Endocrinol Lett VL - 30 ID - Mouslech2009 ER - TY - JOUR AU - Pacher, P. PY - 2006 DA - 2006// TI - The endocannabinoid system as an emerging target of pharmacotherapy JO - Pharmacol Rev VL - 58 UR - https://doi.org/10.1124/pr.58.3.2 DO - 10.1124/pr.58.3.2 ID - Pacher2006 ER - TY - JOUR AU - Castillo, P. E. AU - Younts, T. J. AU - Chávez, A. E. AU - Hashimotodani, Y. PY - 2012 DA - 2012// TI - Endocannabinoid signaling and synaptic function JO - Neuron VL - 76 UR - https://doi.org/10.1016/j.neuron.2012.09.020 DO - 10.1016/j.neuron.2012.09.020 ID - Castillo2012 ER - TY - JOUR AU - Ohno-Shosaku, T. AU - Kano, M. PY - 2014 DA - 2014// TI - Endocannabinoid-mediated retrograde modulation of synaptic transmission JO - Curr Opin Neurobiol VL - 29 UR - https://doi.org/10.1016/j.conb.2014.03.017 DO - 10.1016/j.conb.2014.03.017 ID - Ohno-Shosaku2014 ER - TY - JOUR AU - Elmes, M. W. AU - Kaczocha, M. AU - Berger, W. T. AU - Leung, K. N. AU - Ralph, B. P. AU - Wang, L. PY - 2015 DA - 2015// TI - Fatty acid-binding proteins (FABPs) are intracellular carriers for Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) JO - J Biol Chem VL - 290 UR - https://doi.org/10.1074/jbc.M114.618447 DO - 10.1074/jbc.M114.618447 ID - Elmes2015 ER - TY - JOUR AU - Marzo, V. AU - Maccarrone, M. PY - 2008 DA - 2008// TI - FAAH and anandamide: is 2-AG really the odd one out? JO - Trends Pharmacol Sci VL - 29 UR - https://doi.org/10.1016/j.tips.2008.03.001 DO - 10.1016/j.tips.2008.03.001 ID - Marzo2008 ER - TY - JOUR AU - Zhang, L. AU - Alger, B. E. PY - 2010 DA - 2010// TI - Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome JO - J Neurosci VL - 30 UR - https://doi.org/10.1523/JNEUROSCI.0795-10.2010 DO - 10.1523/JNEUROSCI.0795-10.2010 ID - Zhang2010 ER - TY - JOUR AU - Leweke, F. AU - Piomelli, D. AU - Pahlisch, F. AU - Muhl, D. PY - 2012 DA - 2012// TI - Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia JO - Transl Psychiatry VL - 2 UR - https://doi.org/10.1038/tp.2012.15 DO - 10.1038/tp.2012.15 ID - Leweke2012 ER - TY - JOUR AU - Qin, M. AU - Zeidler, Z. AU - Moulton, K. AU - Krych, L. AU - Xia, Z. AU - Smith, C. B. PY - 2015 DA - 2015// TI - Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome JO - Behav Brain Res VL - 291 UR - https://doi.org/10.1016/j.bbr.2015.05.003 DO - 10.1016/j.bbr.2015.05.003 ID - Qin2015 ER - TY - JOUR AU - Wei, D. AU - Dinh, D. AU - Lee, D. AU - Li, D. AU - Anguren, A. AU - Moreno-Sanz, G. PY - 2016 DA - 2016// TI - Enhancement of anandamide-mediated endocannabinoid signaling corrects autism-related social impairment JO - Cannabis Cannabinoid Res VL - 1 UR - https://doi.org/10.1089/can.2015.0008 DO - 10.1089/can.2015.0008 ID - Wei2016 ER - TY - JOUR AU - Bear, M. F. AU - Huber, K. M. AU - Warren, S. T. PY - 2004 DA - 2004// TI - The mGluR theory of fragile X mental retardation JO - Trends Neurosci VL - 27 UR - https://doi.org/10.1016/j.tins.2004.04.009 DO - 10.1016/j.tins.2004.04.009 ID - Bear2004 ER - TY - JOUR AU - Bakas, T. AU - Nieuwenhuijzen, P. S. AU - Devenish, S. O. AU - McGregor, I. S. AU - Arnold, J. C. AU - Chebib, M. PY - 2017 DA - 2017// TI - The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors JO - Pharmacol Res VL - 119 UR - https://doi.org/10.1016/j.phrs.2017.02.022 DO - 10.1016/j.phrs.2017.02.022 ID - Bakas2017 ER - TY - JOUR AU - Bergamaschi, M. M. AU - Queiroz, R. H. C. AU - Chagas, M. H. N. AU - Oliveira, D. C. G. AU - Martinis, B. S. AU - Kapczinski, F. PY - 2011 DA - 2011// TI - Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients JO - Neuropsychopharmacology VL - 36 UR - https://doi.org/10.1038/npp.2011.6 DO - 10.1038/npp.2011.6 ID - Bergamaschi2011 ER - TY - JOUR AU - Tartaglia, N. AU - Bonn-Miller, M. AU - Hagerman, R. PY - 2019 DA - 2019// TI - Treatment of fragile X syndrome with cannabidiol: a case series study and brief review of the literature JO - Cannabis Cannabinoid Res VL - 4 UR - https://doi.org/10.1089/can.2018.0053 DO - 10.1089/can.2018.0053 ID - Tartaglia2019 ER - TY - JOUR AU - Devinsky, O. AU - Marsh, E. AU - Friedman, D. AU - Thiele, E. AU - Laux, L. AU - Sullivan, J. PY - 2016 DA - 2016// TI - Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial JO - Lancet Neurol VL - 15 UR - https://doi.org/10.1016/S1474-4422(15)00379-8 DO - 10.1016/S1474-4422(15)00379-8 ID - Devinsky2016 ER - TY - JOUR AU - Rohleder, C. AU - Müller, J. K. AU - Lange, B. AU - Leweke, F. M. PY - 2016 DA - 2016// TI - Cannabidiol as a potential new type of an antipsychotic. A critical review of the evidence JO - Front Pharmacol VL - 11 ID - Rohleder2016 ER - TY - JOUR AU - Paudel, K. S. AU - Hammell, D. C. AU - Agu, R. U. AU - Valiveti, S. AU - Stinchcomb, A. L. PY - 2010 DA - 2010// TI - Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers JO - Drug Dev Ind Pharm VL - 36 UR - https://doi.org/10.3109/03639041003657295 DO - 10.3109/03639041003657295 ID - Paudel2010 ER - TY - JOUR PY - 2002 DA - 2002// TI - The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties JO - J Am Acad Child Adolesc Psychiatry VL - 41 UR - https://doi.org/10.1097/00004583-200209000-00006 DO - 10.1097/00004583-200209000-00006 ID - ref24 ER - TY - JOUR AU - Busner, J. AU - Targum, S. D. PY - 2007 DA - 2007// TI - The clinical global impressions scale: applying a research tool in clinical practice JO - Psychiatry (Edgmont) VL - 4 ID - Busner2007 ER - TY - JOUR AU - Esbensen, A. J. AU - Rojahn, J. AU - Aman, M. G. AU - Ruedrich, S. PY - 2003 DA - 2003// TI - Reliability and validity of an assessment instrument for anxiety, depression, and mood among individuals with mental retardation JO - J Autism Dev Disord VL - 33 UR - https://doi.org/10.1023/B:JADD.0000005999.27178.55 DO - 10.1023/B:JADD.0000005999.27178.55 ID - Esbensen2003 ER - TY - JOUR AU - Marshburn, E. C. AU - Aman, M. G. PY - 1992 DA - 1992// TI - Factor validity and norms for the Aberrant Behavior Checklist in a community sample of children with mental retardation JO - J Autism Dev Disord VL - 22 UR - https://doi.org/10.1007/BF01048240 DO - 10.1007/BF01048240 ID - Marshburn1992 ER - TY - JOUR AU - Sansone, S. M. AU - Widaman, K. F. AU - Hall, S. S. AU - Reiss, A. L. AU - Lightbody, A. AU - Kaufmann, W. E. PY - 2012 DA - 2012// TI - Psychometric study of the aberrant behavior checklist in fragile X syndrome and implications for targeted treatment JO - J Autism Dev Disord VL - 42 UR - https://doi.org/10.1007/s10803-011-1370-2 DO - 10.1007/s10803-011-1370-2 ID - Sansone2012 ER - TY - JOUR AU - Russo-Ponsaran, N. M. AU - Yesensky, J. AU - Hessl, D. AU - Berry-Kravis, E. PY - 2014 DA - 2014// TI - Feasibility, reproducibility, and clinical validity of the pediatric anxiety rating scale—revised for fragile X syndrome JO - Am J Intellect Dev Disabil VL - 119 UR - https://doi.org/10.1352/1944-7558-119.1.1 DO - 10.1352/1944-7558-119.1.1 ID - Russo-Ponsaran2014 ER - TY - JOUR AU - Varni, J. W. AU - Seid, M. AU - Rode, C. A. PY - 1999 DA - 1999// TI - The PedsQL™: measurement model for the pediatric quality of life inventory JO - Med Care VL - 37 UR - https://doi.org/10.1097/00005650-199902000-00003 DO - 10.1097/00005650-199902000-00003 ID - Varni1999 ER - TY - JOUR AU - Varni, J. W. AU - Seid, M. AU - Knight, T. S. AU - Burwinkle, T. AU - Brown, J. AU - Szer, I. S. PY - 2002 DA - 2002// TI - The PedsQL in pediatric rheumatology: reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory Generic Core Scales and Rheumatology Module JO - Arthritis Rheum VL - 46 UR - https://doi.org/10.1002/art.10095 DO - 10.1002/art.10095 ID - Varni2002 ER - TY - JOUR AU - Williams, V. S. AU - Morlock, R. J. AU - Feltner, D. PY - 2010 DA - 2010// TI - Psychometric evaluation of a visual analog scale for the assessment of anxiety JO - Health Qual Life Outcomes VL - 8 UR - https://doi.org/10.1186/1477-7525-8-57 DO - 10.1186/1477-7525-8-57 ID - Williams2010 ER - TY - BOOK AU - Guy, W. PY - 1976 DA - 1976// TI - ECDEU assessment manual for psychopharmacology PB - U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs CY - Rockville, MD ID - Guy1976 ER - TY - JOUR AU - Leucht, S. AU - Engel, R. R. PY - 2006 DA - 2006// TI - The relative sensitivity of the clinical global impressions scale and the brief psychiatric rating scale in antipsychotic drug trials JO - Neuropsychopharmacology VL - 31 UR - https://doi.org/10.1038/sj.npp.1300873 DO - 10.1038/sj.npp.1300873 ID - Leucht2006 ER - TY - JOUR AU - Spielmans, G. I. AU - McFall, J. P. PY - 2006 DA - 2006// TI - A comparative meta-analysis of clinical global impressions change in antidepressant trials JO - J Nerv Ment Dis VL - 194 UR - https://doi.org/10.1097/01.nmd.0000244554.91259.27 DO - 10.1097/01.nmd.0000244554.91259.27 ID - Spielmans2006 ER - TY - JOUR AU - Zaider, T. I. AU - Heimberg, R. G. AU - Fresco, D. M. AU - Schneier, F. R. AU - Liebowitz, M. R. PY - 2003 DA - 2003// TI - Evaluation of the clinical global impression scale among individuals with social anxiety disorder JO - Psychol Med VL - 33 UR - https://doi.org/10.1017/S0033291703007414 DO - 10.1017/S0033291703007414 ID - Zaider2003 ER - TY - JOUR AU - Berry-Kravis, E. AU - Hagerman, R. AU - Visootsak, J. AU - Budimirovic, D. AU - Kaufmann, W. E. AU - Cherubini, M. PY - 2017 DA - 2017// TI - Arbaclofen in fragile X syndrome: results of phase 3 trials JO - J Neurodev Disord VL - 9 UR - https://doi.org/10.1186/s11689-016-9181-6 DO - 10.1186/s11689-016-9181-6 ID - Berry-Kravis2017 ER - TY - JOUR AU - Ligsay, A. AU - Dijck, A. AU - Nguyen, D. V. AU - Lozano, R. AU - Chen, Y. AU - Bickel, E. S. PY - 2017 DA - 2017// TI - A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome JO - J Neurodev Disord VL - 9 UR - https://doi.org/10.1186/s11689-017-9207-8 DO - 10.1186/s11689-017-9207-8 ID - Ligsay2017 ER - TY - JOUR AU - Jacquemont, S. AU - Berry-Kravis, E. AU - Hagerman, R. AU - Raison, F. AU - Gasparini, F. AU - Apostol, G. PY - 2014 DA - 2014// TI - The challenges of clinical trials in fragile X syndrome JO - Psychopharmacology (Berl) VL - 231 UR - https://doi.org/10.1007/s00213-013-3289-0 DO - 10.1007/s00213-013-3289-0 ID - Jacquemont2014 ER -